AU1192501A - Fab i inhibitors - Google Patents

Fab i inhibitors

Info

Publication number
AU1192501A
AU1192501A AU11925/01A AU1192501A AU1192501A AU 1192501 A AU1192501 A AU 1192501A AU 11925/01 A AU11925/01 A AU 11925/01A AU 1192501 A AU1192501 A AU 1192501A AU 1192501 A AU1192501 A AU 1192501A
Authority
AU
Australia
Prior art keywords
4alkyl
het
fab
inhibitors
6alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU11925/01A
Other languages
English (en)
Inventor
William H. Miller
Kenneth A. Newlander
Mark A. Seefeld
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU1192501A publication Critical patent/AU1192501A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Semiconductor Lasers (AREA)
AU11925/01A 1999-10-08 2000-10-06 Fab i inhibitors Abandoned AU1192501A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15852999P 1999-10-08 1999-10-08
US60158529 1999-10-08
PCT/US2000/027591 WO2001026654A1 (en) 1999-10-08 2000-10-06 Fab i inhibitors

Publications (1)

Publication Number Publication Date
AU1192501A true AU1192501A (en) 2001-04-23

Family

ID=22568552

Family Applications (1)

Application Number Title Priority Date Filing Date
AU11925/01A Abandoned AU1192501A (en) 1999-10-08 2000-10-06 Fab i inhibitors

Country Status (8)

Country Link
EP (1) EP1225895B1 (https=)
JP (1) JP4961084B2 (https=)
AT (1) ATE294578T1 (https=)
AU (1) AU1192501A (https=)
CO (1) CO5251401A1 (https=)
DE (1) DE60019954T2 (https=)
HK (1) HK1049610A1 (https=)
WO (1) WO2001026654A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
CO5370679A1 (es) 1999-06-01 2004-02-27 Smithkline Beecham Corp Inhibidores fab 1
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6730684B1 (en) * 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
CO5251397A1 (es) * 1999-10-08 2003-02-28 Smithkline Beecham Corp Inhibidores de fab i
ATE285821T1 (de) 1999-10-08 2005-01-15 Affinium Pharm Inc Fab i inhibitoren
KR20030060904A (ko) * 2000-10-06 2003-07-16 뉴로젠 코포레이션 Ｃｒｆ 수용체 조절자로서 벤즈이미다졸 및 인돌 유도체
CA2444597A1 (en) 2001-04-06 2002-10-06 Affinium Pharmaceuticals, Inc. Fab i inhibitors
EP1575951B1 (en) * 2002-12-06 2014-06-25 Debiopharm International SA Heterocyclic compounds, methods of making them and their use in therapy
DE602004016831D1 (de) * 2003-03-17 2008-11-13 Affinium Pharm Inc Pharmazeutische zusammensetzungen inhibitoren von fab i und weitere antibiotika enthaltend
CN101203504B (zh) * 2005-05-03 2012-11-14 兰贝克赛实验室有限公司 抗微生物剂
DK1879877T3 (da) 2005-05-03 2013-04-15 Ranbaxy Lab Ltd Antimikrobielle midler
JP2009533315A (ja) * 2006-04-10 2009-09-17 ランバクシー ラボラトリーズ リミテッド 抗菌剤
EP2687533B1 (en) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamide derivatives as FAB I inhibitors
WO2008098374A1 (en) 2007-02-16 2008-08-21 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab i inhibitors
EP2742047B1 (en) 2011-08-10 2021-05-12 Janssen Sciences Ireland Unlimited Company Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones
US9394295B2 (en) 2011-08-10 2016-07-19 Janssen Sciences Ireland Uc Antibacterial homopiperidinyl substituted 3,4-dihydro-1H-[1,8]naphthyridinones
JO3611B1 (ar) 2011-08-10 2020-08-27 Janssen Sciences Ireland Uc سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم
SI2861608T1 (sl) 2012-06-19 2019-08-30 Debiopharm International Sa Derivati predzdravila (E)-N-metil-N-((3-metilbenzofuran-2-IL)metil)- 3-(7-okso-5,6,7,8-tetrahidro-1 ,8-nafthiridin-3-il)akrilamid
CN104981466B (zh) 2012-08-10 2019-06-14 爱尔兰詹森科学公司 抗细菌化合物
MX363480B (es) 2012-08-10 2019-03-22 Janssen Sciences Ireland Uc Compuestos bacterianos que constan de un grupo heterocicloalquilo basado en nitrógeno que contiene un doble enlace unido a carbonilo que inhiben la enzima fabi.
BR122023021456A2 (pt) 2016-02-26 2024-02-20 Debiopharm International S.A. Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
LT3923914T (lt) 2019-02-14 2023-07-25 Debiopharm International S.A. Afabicino kompozicija, jos gamybos būdas
CN113939306B (zh) 2019-06-14 2024-07-19 德彪药业国际股份公司 用于治疗涉及生物膜的细菌感染的药物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207679B1 (en) * 1997-06-19 2001-03-27 Sepracor, Inc. Antimicrobial agents uses and compositions related thereto
US5932743A (en) * 1997-08-21 1999-08-03 American Home Products Corporation Methods for the solid phase synthesis of substituted indole compounds

Also Published As

Publication number Publication date
HK1049610A1 (zh) 2003-05-23
DE60019954D1 (en) 2005-06-09
WO2001026654A1 (en) 2001-04-19
JP2003511415A (ja) 2003-03-25
DE60019954T2 (de) 2006-02-23
EP1225895A1 (en) 2002-07-31
ATE294578T1 (de) 2005-05-15
JP4961084B2 (ja) 2012-06-27
EP1225895B1 (en) 2005-05-04
CO5251401A1 (es) 2003-02-28
EP1225895A4 (en) 2002-11-13

Similar Documents

Publication Publication Date Title
AU1192501A (en) Fab i inhibitors
DE60029235D1 (en) Fab-i-hemmer
TR200103485T2 (tr) Antibakteriyel bileşikler.
AU2560300A (en) Acetamido acetonitrile derivatives as inhibitors of cathepsin l and/or cathepsins
WO2001022953A3 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
MXPA04001889A (es) Inhibidores de la alquin-aril fosfodiesterasa-4.
AU2002351752A1 (en) Combined use of a glp-1 compound and another drug for treating dyslipidemia
HK1049656A1 (zh) Fab i抑制剂
CA2402742A1 (en) Method of treating or inhibiting colonic polyps
GB0005251D0 (en) Therapeutic compounds
WO2002057252A3 (en) Heterocyclic sulfonamide inhibitors of beta amyloid production
NZ544009A (en) Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain
NO996108L (no) 9-oksinerytromycinderivater
WO2003053359A3 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
MXPA03010761A (es) Combinaciones farmaceuticas.
WO2002016312A3 (de) NEUE VERBINDUNGEN, DIE FAKTOR Xa-AKTIVITÄT INHIBIEREN
IL149586A0 (en) Pyrimidine derivatives as selective inhibitors of cox-2
WO2003053971A8 (en) Pyridoquinoxaline antivirals
WO2003049690A3 (en) Hiv integrase inhibitors
EP1347759A4 (en) ANTIBACTERIAL CONNECTIONS
GEP20053626B (en) Substituted 8-Arylquinoline Phosphodiesterase-4 Inhibitors, Pharmaceutical Composition Containing Them and Use Thereof
HK1053833A1 (zh) 取代苯基法呢基转移酶抑制剂
CA2316082A1 (en) Substituted 2-benzylamino-2-phenyl-acetamide compounds
IL162689A0 (en) Methods of using conjugates of saccharides and acetamidino or guanidino compounds for treating bacterial infections
AU2002359150A1 (en) Therapeutic heterocycles

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase